Deep Vein Thrombosis Prophylaxis: State of the Art

被引：5

作者：

Lieberman, Jay R. ^{[1
]}

机构：

[1] Univ Southern Calif, Dept Orthopaed Surg, Keck Sch Med, 1520 San Pablo St,Suite 2000, Los Angeles, CA 90033 USA

来源：

JOURNAL OF ARTHROPLASTY | 2018年 / 33卷 / 10期

关键词：

pulmonary embolism; deep vein thrombosis; chemoprophylaxis; risk stratification; anticoagulation; TOTAL HIP-ARTHROPLASTY; VENOUS THROMBOEMBOLIC DISEASE; KNEE ARTHROPLASTY; AMERICAN-COLLEGE; PREVENTION; GUIDELINES; ASPIRIN;

D O I：

10.1016/j.arth.2018.01.051

中图分类号：

R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学（修复外科学）];

学科分类号：

摘要：

The selection of a prophylaxis regimen to prevent symptomatic pulmonary embolism and deep vein thrombosis is a balance between efficacy and safety. The latest American Academy of Orthopaedic Surgeons guideline recommended that either chemoprophylaxis or mechanical prophylaxis be used after total joint arthroplasty but did not recommend specific agents. However, the latest evidence-based American College of Chest Physicians guideline recommended a variety of chemoprophylaxis and mechanical agents for a minimum of 10 to 14 days after total joint arthroplasty. Risk stratification is the key to the selection of the appropriate prophylaxis regimen for the individual patient, but the optimal risk stratification protocol still needs to be developed. (C) 2018 Elsevier Inc. All rights reserved.

引用

页码：3107 / 3108

页数：2